Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688428.SS
HOLDREMOVEInnoCare Pharma Limited · Healthcare · China · $6.4B · Avg Vol: $34M/d
InnoCare Pharma is a pre-profit biotech company with high R&D cash burn, failing our requirement for established owner earnings and high ROIC.
COMPANY DESCRIPTION
InnoCare Pharma Limited discovers and develops novel therapies for oncology and autoimmune diseases, led by its commercialized BTK inhibitor, orelabrutinib. The company possesses a robust, proprietary drug discovery platform with a pipeline of highly selective small molecules and biologics. It is a biopharmaceutical innovator with dual listings and a strong focus on global clinical development and commercialization.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Revenue | 154M | 92M | 109M | 149M | -1.1% |
| EPS | -0.01 | -0.09 | -0.05 | -0.04 | — |
| Shares | 1.5B | 1.8B | 1.8B | 1.8B | +17.5% |
| Debt | 187M | 185M | 199M | 188M | 0.1% |
| Equity | 828M | 1.1B | 1.1B | 994M | 6.3% |
| Op CF | 25M | -84M | -99M | -54M | — |
| Inv CF | -256M | -255M | 99M | 164M | — |
| Fin CF | 376M | 457M | 193,314 | -42M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688428.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688428.SS | InnoCare Pharma Limited(you) | $6.4B | 40 | HOLD |
| 9995.HK | RemeGen Co., Ltd. | $6.3B | 40 | HOLD |
| 300759.SZ | Pharmaron Beijing Co., Ltd. | $6.8B | 44 | HOLD |
| 002252.SZ | Shanghai RAAS Blood Products Co., Ltd. | $5.2B | 34 | SELL |
| 2696.HK | Shanghai Henlius Biotech, Inc. | $4.8B | 45 | HOLD |
| 600161.SS | Beijing Tiantan Biological Products Co., Ltd. | $4.0B | 46 | HOLD |
| 603392.SS | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | $6.5B | 22 | SELL |
| 688180.SS | Shanghai Junshi Biosciences Co., Ltd. | $5.2B | 25 | SELL |
| 300122.SZ | Chongqing Zhifei Biological Products Co., Ltd. | $4.8B | 25 | SELL |
| 301301.SZ | Yili Chuanning Biotechnology Co.,Ltd. | $2.9B | 45 | HOLD |
Peer medians: ROE 4.7% · P/E 27.8x · Gross margin 52.9%